GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Down 26.7% in March

GT Biopharma, Inc. (NASDAQ:GTBP) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 747,375 shares, a decrease of 26.7% from the March 15th total of 1,019,371 shares. Based on an average daily trading volume, of 654,579 shares, the short-interest ratio is currently 1.1 days. Currently, 2.5% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of GT Biopharma in a report on Friday, April 10th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

GT Biopharma Stock Down 5.0%

NASDAQ GTBP traded down $0.02 during trading hours on Friday, hitting $0.38. 351,318 shares of the company were exchanged, compared to its average volume of 1,077,467. The stock has a 50-day moving average price of $0.44 and a 200 day moving average price of $0.61. GT Biopharma has a 52 week low of $0.35 and a 52 week high of $3.85. The stock has a market cap of $11.96 million, a PE ratio of -0.06 and a beta of 1.19.

Institutional Trading of GT Biopharma

An institutional investor recently bought a new position in GT Biopharma stock. SeaCrest Wealth Management LLC bought a new stake in shares of GT Biopharma, Inc. (NASDAQ:GTBP) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $37,000. SeaCrest Wealth Management LLC owned about 0.47% of GT Biopharma as of its most recent SEC filing. 8.15% of the stock is currently owned by institutional investors.

GT Biopharma Company Profile

GT Biopharma, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel immuno-oncology therapies utilizing its proprietary Tri-specific NK cell engager (TriKE) platform. This technology is designed to harness and enhance the body’s natural killer (NK) cells by simultaneously binding tumor antigens and interleukin-15 (IL-15), stimulating NK cell proliferation and targeted cytotoxicity. By focusing on NK cell engagement rather than T-cell activation, the company aims to offer therapies with potentially improved safety profiles and reduced immune-related adverse events.

The company’s lead candidate, GTB-3550, is currently in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).